National Psychosis Service, South London and Maudsley NHS Foundation Trust, London, UK.
Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK.
BMC Psychiatry. 2017 Dec 28;17(1):413. doi: 10.1186/s12888-017-1571-0.
People with psychosis have a reduced life expectancy of 10-20 years, largely due to cardiovascular disease. This trial aimed to determine the effectiveness of a modular health promotion intervention (IMPaCT Therapy) in improving health and reducing cardiovascular risk in psychosis.
A multicentre, two arm, parallel cluster RCT was conducted across five UK mental health NHS trusts. Community care coordinators (CC) were randomly assigned to training and supervision in delivering IMPaCT Therapy or treatment as usual (TAU) to current patients with psychosis (cluster). The primary outcome was the physical and mental health subscales of the Short form-36 (SF-36) questionnaire.
Of 104 care coordinators recruited, 52 (with 213 patients) were randomised to deliver IMPaCT therapy and 52 (with 193 patients) randomised to TAU. Of 406 patients, 318 (78%) and 301 (74%) attended 12- and 15-month follow-up respectively. IMPaCT therapy showed no significant effect on the physical or mental health component SF-36 scores versus TAU at 12 or 15 months. No effect was observed for cardiovascular risk indicators, except for HDL cholesterol, which improved more with IMPACT therapy than TAU (Treatment effect (95% CI); 0.085 (0.007 to 0.16); p = 0.034). The 22% of patients who received >180 min of IMPACT Therapy in addition to usual care achieved a greater reduction in waist circumference than did controls, which was clinically significant.
Training and supervising community care coordinators to use IMPaCT therapy in patients with psychosis is insufficient to significantly improve physical or mental health quality of life. The search for effective, pragmatic interventions deliverable in health care services continues.
The trial was retrospectively registered with ISRCTN registry on 23/4/2010 at ISRCTN58667926 ; recruitment started on 01/03/2010 with first randomization on 09.08.2010 ISRCTN58667926 .
精神病患者的预期寿命减少了 10-20 年,这主要是由于心血管疾病。本试验旨在确定模块化健康促进干预(IMPaCT 疗法)在改善精神疾病患者的健康和降低心血管风险方面的有效性。
在英国五家 NHS 心理健康信托机构进行了一项多中心、两臂、平行集群 RCT。社区护理协调员(CC)被随机分配接受 IMPaCT 疗法的培训和监督,或接受当前精神病患者的常规治疗(TAU,集群)。主要结果是短期健康调查-36(SF-36)问卷的身体和心理健康子量表。
在招募的 104 名护理协调员中,52 名(213 名患者)被随机分配接受 IMPaCT 治疗,52 名(193 名患者)随机分配接受 TAU。在 406 名患者中,分别有 318 名(78%)和 301 名(74%)在 12 个月和 15 个月时进行了随访。与 TAU 相比,IMPACT 疗法在 12 个月或 15 个月时对身体或心理健康成分 SF-36 评分均无显著影响。心血管风险指标没有观察到效果,除了高密度脂蛋白胆固醇,IMPACT 治疗组比 TAU 组改善更多(治疗效果(95%CI);0.085(0.007 至 0.16);p=0.034)。与对照组相比,接受超过 180 分钟的 IMPACT 治疗外加常规护理的 22%患者的腰围减少更显著,这具有临床意义。
培训和监督社区护理协调员在精神病患者中使用 IMPaCT 疗法不足以显著改善身体或心理健康的生活质量。仍在继续寻找可在医疗保健服务中提供的有效、实用的干预措施。
该试验于 2010 年 4 月 23 日在 ISRCTN 注册处进行了回顾性登记,登记号为 ISRCTN58667926;招募工作于 2010 年 3 月 1 日开始,首次随机分组于 2010 年 8 月 9 日进行 ISRCTN58667926。